Hasty Briefsbeta

Bilingual

NPLOC4 Inhibition Remodels Tumor Microenvironment via M2-to-M1 Macrophage Reprogramming and Boosts Anti-PD-1 Response in Liver Cancer - PubMed

3 days ago
  • #immunotherapy
  • #hepatocellular carcinoma
  • #NPLOC4
  • NPLOC4 inhibition remodels the tumor microenvironment by reprogramming M2 macrophages to M1, enhancing anti-PD-1 response in liver cancer.
  • NPLOC4+ TAMs inhibit antitumor immune responses by promoting RIG-I degradation, negatively impacting HCC patient prognosis.
  • NPLOC4 suppresses the type I interferon pathway in TAMs, promotes M2 polarization, and reduces CD8+ T-cell infiltration, creating an immunosuppressive HCC microenvironment.
  • Disulfiram/copper (DSF/Cu) targets NPLOC4, and combining DSF/Cu with PD-1 therapy significantly inhibits HCC growth.
  • Targeting NPLOC4+ TAMs enhances resistance to anti-PD-1 therapy, presenting a novel immune target for HCC treatment.